Approval for addition of pertuzumab in the labeling of her2 fish pharmdx kit. the device, as modified, will be marketed under the trade name her2 fish pharmdx kit and its indication for use is: a direct fluorescence in situ hybridization (fish) assay designed toquantitatively determine her2 gene amplification in formalin-fixed, paraffin-embedded (ffpe) breast cancer tissue specimens and ffpe specimens from patients with metastatic gastric or gastroesophageal junction adenocarcinoma.  Her2 fish pharmdx kit is indicated as an aid in the assessment of breast and gastric cancer patients for whom herceptin (trastuzumab) treatment is being considered and for breast cancer patients for whom perjeta (pertuzumab) treatment is being considered (see herceptin and perjeta package inserts).